Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest Chronic myelogenous leukemia Stories

2012-02-27 07:26:30

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that imatinib is the treatment of choice for these patients. Imatinib, a drug that blocks the protein made by a particular cancer-causing gene, has revolutionized the treatment and...

2012-02-17 17:50:00

According to court documents, on Jan. 18th, 2012 Norvel Dorsey, a Texas man, filed the lawsuit No. B-0191669 in Jefferson County District Court, Texas. Mr. Dorsey accuses DuPont De Nemours, Exxon Mobil Corp. and some of its subsidiaries, Foster Wheeler Energy Corp., Gulf Oil Corp., Texaco, U.S. Steel, Chevron U.S.A., and 4520 Corp. alleging that he developed leukemia from benzene exposure. Benzene is a petroleum product, originally manufactured from coal tar that is used as a component in...

2012-02-13 23:02:08

New research takes aim at stubborn cancer stem cells that are thought to be responsible for treatment resistance and relapse. The study, published by Cell Press in the February 14 issue of the journal Cancer Cell, provides insight into mechanisms associated with the survival of leukemia stem cells and identifies a potential therapeutic target that is specific for these dangerously persistent cells. Chronic myelogenous leukemia (CML) is a cancer of the white blood cells for which tyrosine...

2012-01-31 17:14:00

Confirmatory trials show significantly prolonged survival in patients; drug granted regular approval SILVER SPRING, Md., Jan. 31, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today's action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the...

2012-01-30 10:35:30

About one in five or six cases of adult leukemia in Western populations relates to so-called chronic myeloid leukemia, or CML.  Treatment of CML usually relies on inhibitors of the abnormal protein that causes the condition but some patients do not respond to treatment and efforts are underway to develop a supplementary approach, targeting the so-called JAK2 kinase.  Recent results from the groups of Veronika Sexl at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna)...

2012-01-23 22:10:03

Although significant progress has been made in treating chronic myeloid leukemia, the disease cannot yet be eliminated in all patients, and that challenge must be addressed, states a commentary in CMAJ (Canadian Medical Association Journal). Likening the journey to find a cure for chronic myeloid leukemia as a marathon, cancer expert Dr. Jorge Cortes, University of Texas, MD Anderson Cancer Center, Houston, Texas, writes, "The past half century has been an extraordinary run that has us on...

2012-01-12 06:48:00

PHOENIX,, Jan. 12, 2012 /PRNewswire/ -- Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that has initiated the development of Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults. In children the drug has demonstrated a powerful action against Chronic Myeloid Leukemia, possibly one of the most prescribed...

2011-12-23 08:38:05

Research includes phase III bone marrow transplant study presented as first abstract in the scientific plenary session Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers — leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego. Research...

2011-12-22 15:26:24

A compound produced from fish oil that appears to target leukemia stem cells could lead to a cure for the disease, according to Penn State researchers. The compound -- delta-12-protaglandin J3, or D12-PGJ3 -- targeted and killed the stem cells of chronic myelogenous leukemia, or CML, in mice, said Sandeep Prabhu, associate professor of immunology and molecular toxicology in the Department of Veterinary and Medical Sciences. The compound is produced from EPA -- Eicosapentaenoic Acid -- an...

2011-12-12 16:51:00

EAST HANOVER, N.J., Dec. 12, 2011 /PRNewswire/ -- Phase III clinical trial data presented today contribute to the growing evidence that adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who are treated with Tasigna® (nilotinib) have deeper levels of response compared to those treated with Gleevec® (imatinib mesylate) tablets(*1,2). The findings from the ENEST (Evaluating...